Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2022 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement

Fort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
June 21, 2022 08:15 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces FDA Clearance of IND for NXP800

FORT LEE, NJ,, June 21, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
June 13, 2022 08:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
May 20, 2022 10:21 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference

FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
May 10, 2022 08:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights

Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing NXP800 Unique Discovery and Optimization Program Showcased at the 2022 AACR “New Drugs on the Horizon” Session NXP900 Preclinical...
April 13, 2022 08:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference

Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
April 11, 2022 08:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference

Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
March 22, 2022 08:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights

Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds Initiated Phase 1a Clinical Trial for NXP800 Announced Promising Data for NXP900 in Triple Negative...
March 10, 2022 08:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting

Fort Lee, NJ, March 10, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for...
March 09, 2022 10:12 ET | Source: Nuvectis Pharma, Inc.

Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference

Fort Lee, NJ, March 09, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...